- Home
- KPTI
as 07-26-2024 4:00pm EST
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEWTON |
| Market Cap: | 121.2M | IPO Year: | 2013 |
| Target Price: | $4.60 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $1.95 | Next Earning Date: | 08-05-2024 |
| Revenue: | $140,461,000 | Revenue Growth: | -5.16% |
| Revenue Growth (this year): | 1.19% | Revenue Growth (next year): | 13.15% |
Stock Insider Trading Activity of Karyopharm Therapeutics Inc. (KPTI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paulson Richard A. | KPTI | President and CEO | Jul 5 '24 | Sell | $0.85 | 3,616 | $3,077.22 | 1,146,489 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | Jun 5 '24 | Sell | $0.96 | 463,518 | $444,142.95 | 346,615 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | Jun 5 '24 | Sell | $0.96 | 4,526 | $4,336.81 | 3,385 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | Jun 5 '24 | Sell | $0.98 | 117,307 | $115,289.32 | 229,308 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | Jun 5 '24 | Sell | $0.98 | 1,145 | $1,125.31 | 2,240 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | Jun 5 '24 | Sell | $0.95 | 229,308 | $218,003.12 | 0 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | Jun 5 '24 | Sell | $0.95 | 2,240 | $2,129.57 | 0 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Jun 4 '24 | Sell | $0.99 | 3,592 | $3,556.08 | 1,150,105 | SEC Form 4 |
| Mason Michael | KPTI | EVP, CFO & Treasurer | Jun 4 '24 | Sell | $0.99 | 652 | $645.48 | 398,104 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | May 31 '24 | Sell | $0.95 | 1,976 | $1,885.10 | 14,697 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | May 31 '24 | Sell | $1.00 | 357,256 | $357,506.08 | 1,147,875 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | May 31 '24 | Sell | $1.00 | 3,488 | $3,490.44 | 11,209 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | May 31 '24 | Sell | $0.95 | 337,742 | $321,564.16 | 810,133 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | May 31 '24 | Sell | $0.95 | 3,298 | $3,140.03 | 7,911 | SEC Form 4 |
| PAKIANATHAN DEEPIKA | KPTI | Director | May 31 '24 | Sell | $0.95 | 202,418 | $193,106.77 | 1,505,131 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | May 6 '24 | Sell | $1.13 | 3,576 | $4,040.88 | 1,153,697 | SEC Form 4 |
| Rangwala Reshma | KPTI | EVP & Chief Medical Officer | Apr 22 '24 | Sell | $1.17 | 6,789 | $7,943.13 | 342,931 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Apr 4 '24 | Sell | $1.29 | 3,563 | $4,596.27 | 1,157,273 | SEC Form 4 |
| Paulson Richard A. | KPTI | President and CEO | Mar 5 '24 | Sell | $1.30 | 3,573 | $4,644.90 | 1,160,836 | SEC Form 4 |
| Rangwala Reshma | KPTI | EVP & Chief Medical Officer | Feb 29 '24 | Sell | $1.20 | 5,969 | $7,162.80 | 349,720 | SEC Form 4 |
| Rangwala Reshma | KPTI | EVP & Chief Medical Officer | Feb 29 '24 | Sell | $1.17 | 15,667 | $18,330.39 | 355,689 | SEC Form 4 |
| Poulton Stuart | KPTI | EVP, Chief Development Officer | Feb 29 '24 | Sell | $1.17 | 16,311 | $19,083.87 | 335,666 | SEC Form 4 |
| Poulton Stuart | KPTI | EVP, Chief Development Officer | Feb 29 '24 | Sell | $1.20 | 6,155 | $7,386.00 | 329,511 | SEC Form 4 |
| Cheng Sohanya Roshan | KPTI | EVP & Chief Commercial Officer | Feb 29 '24 | Sell | $1.17 | 21,840 | $25,552.80 | 398,618 | SEC Form 4 |
| Cheng Sohanya Roshan | KPTI | EVP & Chief Commercial Officer | Feb 29 '24 | Sell | $1.20 | 5,109 | $6,130.80 | 393,509 | SEC Form 4 |
Latest Karyopharm Therapeutics Inc. News
KPTI Breaking Stock News: Dive into KPTI Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?
Insider Monkey
11 days ago
Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?
PR Newswire
25 days ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $7 From $8, Maintains Buy Rating
PR Newswire
2 months ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
2 months ago
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
PR Newswire
2 months ago
Karyopharm to Participate at the Jefferies Global Healthcare Conference
Simply Wall St.
3 months ago
Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Compare KPTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KPTI Karyopharm Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.